Special Issue

Precision Medicine on Hypertension and Cardiovascular Diseases

Message from the Guest Editor

The personalization of pharmacological therapy for patients with cardiovascular disease represents one of the most interesting challenges of modern cardiology. Precision medicine intends to focus on relevant topics of daily clinical practice such as arterial hypertension, diabetes, heart failure, hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD). In the field of therapy optimization and personalization, scientific research has introduced interesting innovations, and many others are underway (for example, SGLT2, PCSK9i, siRNA, antisense oligonucleotide). These novel therapies have the potential to enhance drug delivery, reduce off-target effects, and provide prolonged therapeutic effects, improving patient outcomes. By targeting the root causes of cardiovascular diseases at the molecular level, these innovative therapies offer the hope for improving patient outcomes and reducing the global burden of cardiovascular morbidity and mortality. In this Special Issue, we welcome your submission of reviews, communications, and original research articles targeting any of these topics.

Guest Editor

Dr. Egidio Imbalzano

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

Deadline for manuscript submissions

closed (10 May 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/174350

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

